Drug giant Pfizer is in talks to buy biotech Seagen in a deal that would be worth at least $30bn, say Jared Hopkins and Jonathan Rockoff in The Wall Street Journal. Seagen has pioneered
Pfizer targets biotech’s cancer drug
Mar 03, 2023
1 minute
You’re reading a preview, subscribe to read more.
Start your free 30 days